A randomized, double-blind, placebo-controlled trial of trametinib, a MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.
Jeffrey R. Infante
Consultant or Advisory Role - GlaxoSmithKline (U)
Bradley G. Somer
No relevant relationships to disclose
Joon Oh Park
No relevant relationships to disclose
Chung-Pin Li
No relevant relationships to disclose
Max E. Scheulen
Research Funding - GlaxoSmithKline
Saifuddin M. Kasubhai
No relevant relationships to disclose
Do-Youn Oh
No relevant relationships to disclose
Yuan Liu
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Soumi Lahiri
Employment or Leadership Position - GlaxoSmithKline
Klaudia Steplewski
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Ngocdiep T. Le
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline